A perspective on potential antibody-dependent enhancement of SARS-CoV-2

@article{Arvin2020APO,
  title={A perspective on potential antibody-dependent enhancement of SARS-CoV-2},
  author={Ann M. Arvin and Katja Fink and Michael Alexander Schmid and Andrea L. Cathcart and Roberto Spreafico and Colin Havenar-Daughton and Antonio Lanzavecchia and Davide Corti and Herbert W. Virgin},
  journal={Nature},
  year={2020},
  pages={1-11}
}
Antibody-dependent enhancement (ADE) of disease is a general concern for the development of vaccines and antibody therapies because the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in the pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2… Expand
SARS-CoV-2 Infection and Antibody-Dependent Enhancement
  • A. Bastug, H. Bodur
  • Medicine
  • Understanding COVID-19: The Role of Computational Intelligence
  • 2021
TLDR
Literature findings revealing the factors with an impact on eliciting NAbs, possible mechanisms and risks of ADE, and safety concerns for SARS-CoV-2 treatment interventions are outlined are outlined. Expand
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
TLDR
There is a wide breadth of antibody responses against SARS-CoV-2 in patients that differentially correlate with virus neutralization, and it is found that neutralization is mediated mainly by antibodies directed against the spike protein of SAR's co-ordinated virus in general and the receptor binding site in particular. Expand
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment forExpand
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
TLDR
Key discoveries on the humoral immune responses in COVID-19 are introduced, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants are introduced. Expand
Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
TLDR
The rationale for developing COVID-19 vaccines is summarized, novel insights into vaccine development from a pharmaceutical science perspective are provided and multiple clinical trial outcomes of novel vaccines in terms of safety and efficacy are reviewed. Expand
Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
TLDR
The current understanding of B and T cells immune responses and activity in SARS-CoV-2 pathogenesis is discussed, pointing towards a link between T cell function and disease severity. Expand
Prospects for a safe COVID-19 vaccine
TLDR
Evaluated research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease finds neither principles of immunity nor preclinical studies provide a basis for prioritizing among the CO VID-19 vaccine candidates with respect to safety. Expand
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
TLDR
The onset and persistence of IgA, IgM and IgG antibodies, and their roles in neutralising SARS-CoV-2, their persistence in convalescent individuals, and in reinfection are reviewed. Expand
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
TLDR
While in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can occur in SARS-CoV-2 antibody-infused macaques, and both types of infection-enhancing antibodies protected from Sars-Cov-2 replication in monkeys and mice. Expand
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
TLDR
While in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques, and both types of infection-enhancing antibodies protected from Sars-Cov-2 replication in monkeys and mice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 174 REFERENCES
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
TLDR
A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. Expand
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
TLDR
Quantitative-PCR and immunofluorescence staining results indicate that SARS-CoV is capable of replication in HL-CZ cells, and of displaying virus-induced cytopathic effects and increased levels of TNF-α, IL-4 and IL-6 two days post-infection, while data from infectivity assays indicate that antibodies against SARsCoV spike proteins may trigger ADE effects. Expand
A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease
TLDR
While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research. Expand
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
TLDR
The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19 and discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis. Expand
Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.
TLDR
It is demonstrated that anti-spike antibodies potentiate infection of both monocytic and lymphoid human immune cell lines with SARS-CoV Spike-pseudotyped lentiviral particles and also with replicationcompetent Sars-coronavirus. Expand
Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
TLDR
It is demonstrated that human macrophages can be infected by SARS-CoV as a result of IgG-mediated ADE and indicates that this infection route requires signaling pathways activated downstream of binding to FcγRII receptors. Expand
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
TLDR
Analysis of plasma from patients infected by SARS-CoV-2 or SARV, and from infected or immunized mice shows cross-reactivity in antibody binding to the spike protein is common, but cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Expand
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
TLDR
Results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Expand
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
TLDR
The isolation of a potent MERS-CoV–neutralizing antibody from memory B cells of an infected individual is described, for the first time, and this antibody, named LCA60, binds to a novel site on the spike protein and potently neutralizes infection of multiple MSPs isolates by interfering with the binding to the cellular receptor CD26. Expand
Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics
TLDR
Mab-induced destabilization of the influenza HA stem domain, faster kinetics of influenza virus fusion, and ERD in vivo are described, underlines careful preclinical evaluation of next-generation influenza vaccines or antibody-based therapeutics that do not block influenza virus receptor binding. Expand
...
1
2
3
4
5
...